caski human cervical cancer cell lines (ATCC)
Structured Review

Caski Human Cervical Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1725 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/caski+human+cervical+cancer+cell+lines/Ca+Ski/pmc11176388-33-3-13
Average 97 stars, based on 1725 article reviews
Images
1) Product Images from "PCK1-mediated glycogenolysis facilitates ROS clearance and chemotherapy resistance in cervical cancer stem cells"
Article Title: PCK1-mediated glycogenolysis facilitates ROS clearance and chemotherapy resistance in cervical cancer stem cells
Journal: Scientific Reports
doi: 10.1038/s41598-024-64255-6
Figure Legend Snippet: ( A – C ) HCC94, and CaSki human cervical cancer cells were sorted into two fractions: CD133 + and CD133 − . After treatment with cisplatin (50 μM) for 48 h, measurements were taken for cell viability ( A ), NADPH/NADP + ratio ( B ), and reactive oxygen species (ROS) levels ( C ). ( D ) HCC94 and CaSki human cancer stem cells or bulk cells were treated with PBS and cisplatin (50uM) for 48 h. The levels of R5P/Ru5P, S7P and 6-PGA (6-phosphogluconic acid) were measured. ( E – G ) HCC94, and CaSki human cancer stem cells or bulk cells were treated with cisplatin (50 μM) or G6PDi (50 μM) for 48 h. NADPH ( E ), ROS ( F ), and cell viability ( G ) levels were measured. Data are presented as mean ± SEMs of three independent experiments. ***P < 0.001. Two-tailed student’s t -test ( A – D ) or one-way analysis of variance (ANOVA) followed by Bonferroni’s test ( E – G ).
Techniques Used: Two Tailed Test
Figure Legend Snippet: ( A – B ) HCC94 and CaSki human cervical cancer cells then sorted into two fractions: CD133 + (CSC), CD133 − (bulk cell). Glycogen levels was measured ( A ). The expression of p-PYGL and PYGL in CSC or bulk cell was measured ( B ). ( C ) The level of glycogen was measured in patients with chemotherapy-resistant or -sensitive cancers. ( D ) The level of p-PYGL was measured in patients with chemotherapy-resistant or -sensitive cancers by IF. In ( C – D ), n = 6 patients. The data were presented as means ± SEMs of three independent experiments. ***P < 0.001. Two-tailed student’s t -test ( A , C , D ).
Techniques Used: Expressing, Two Tailed Test
Figure Legend Snippet: ( A – E ) HCC94 and CaSki human cancer stem cells, which was transfected with PYGL siRNA, were treated with PBS or cisplatin for 48 h. The level of glycogen ( A ), m+5 R5P, m+7 S7P, m+6 6-PGA ( B ), NADPH/NADP + ratio ( B ), ROS ( C ) and cell viability ( D ) was measured. ( F – J ) HCC94 and CaSki human cancer stem cells, which was transfected with GYS1 siRNA, were treated with PBS or cisplatin for 48 h. The level of glycogen ( F ), m+5 R5P, m+7 S7P, m+6 6-PGA ( G ), NADPH/NADP + ratio ( H ), ROS ( I ) and cell viability ( J ) was measured. The data were presented as means ± SEMs of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. One-way analysis of variance (ANOVA) followed by Bonferroni’s test ( A – H ).
Techniques Used: Transfection
Figure Legend Snippet: ( A – D ) HCC94 and CaSki human cancer stem cells, which was pretreated with okadaic acid (OA, 1 0 nM), were treated with cisplatin for 48 h. The level of NADPH/NADP + ( A ), m+5 R5P, m+7 S7P, m+6 6-PGA ( B ), ROS ( C ) and cell viability ( D ) was measured. ( E ) The level of p-PYGL and PYGL was measured in HCC94 and CaSki human cancer stem cells, which was pretreated with OA. ( F ) The level of PCK1 was measured in HCC94 and CaSki human cancer stem cells or bulk cell. ( G – K ) HCC94 and CaSki human cancer stem cells, which was transfected with PCK1 siRNA, were treated with cisplatin for 48 h. The level of NADPH/NADP + ratio ( G ), m + 5 R5P, m + 7 S7P, m + 6 6-PGA ( H ), ROS ( I ) and Cell viability ( J ) were measured. The data were presented as means ± SEMs of three independent experiments. **P < 0.01, ***P < 0.001. One-way analysis of variance (ANOVA) followed by Bonferroni’s test ( A – D , G – J ).
Techniques Used: Transfection
Figure Legend Snippet: ( A ) HCC94 and CaSki human cancer stem cells, which was transfected with PCK1 siRNA, were treated with cisplatin for 48 h. The level of p-PYGL and PYGL was measured ( A ). ( B ) Immunoblot of immunoprecipitations of PYGL or PCK1 in lysates from cancer stem cells or bulk cells treated with cisplatin for 24 h. ( C ) Immunoblot of immunoprecipitations of PP1c or PYGL in lysates from cancer stem cells was transfected with PCK1 siRNA.
Techniques Used: Transfection, Western Blot
Related Articles
Incubation:Article Title: Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study. Article Snippet: .. The HeLa and other:Article Title: Gemcitabine and carboplatin demonstrate synergistic cytotoxicity in cervical cancer cells by inhibiting DNA synthesis and increasing cell apoptosis Article Snippet: SiHa and |
